e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants
L. Bertoletti, X. Delavenne, D. Montani, J.C. Lega, M. Humbert, P. Mismetti (Saint-Etienne, Kremlin-Bicêtre, Clamart, France)
Source:
Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Session:
Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Session type:
Poster Discussion
Number:
1510
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Bertoletti, X. Delavenne, D. Montani, J.C. Lega, M. Humbert, P. Mismetti (Saint-Etienne, Kremlin-Bicêtre, Clamart, France). Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants. Eur Respir J 2012; 40: Suppl. 56, 1510
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Initial dual oral combination therapy in pulmonary arterial hypertension
Source: Eur Respir J 2016; 47:1727-1736
Year: 2016
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Therapeutic limitations of oral medications to normalize hemodynamics in patients with pulmonary artery hypertension.
Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Year: 2019
Novel therapeutic perspectives in pulmonary arterial hypertension
Source: Eur Respir J 2003; 22: 193-194
Year: 2003
Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Year: 2020
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010
Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007
Applying pharmacogenomics to pulmonary arterial hypertension (PAH): A target-based approach to therapy
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
The role of combination therapy in managing pulmonary arterial hypertension
Source: Eur Respir Rev 2014; 23: 469-475
Year: 2014
Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 461s
Year: 2003
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Challenges in the diagnosis and treatment of pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21: 313-320
Year: 2012
Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Optimal management of severe pulmonary arterial hypertension
Source: Eur Respir Rev 2011; 20: 254-261
Year: 2011
Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options
Source: Eur Respir Rev 2009; 18: 24-28
Year: 2009
Lung ventilation function before and after therapy of arterial hypertension by different antihypertensive drugs
Source: Eur Respir J 2003; 22: Suppl. 45, 48s
Year: 2003
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights
Source: Eur Respir J 2015; 46: 414-421
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept